Zydus Cadila Receives Us Fda Approval For Mesalamine Er Capsules
Zydus Cadila Has Received Final Approval From The Us Food And Drug Administration (Fda) To Market Mesalamine Extended-Release Capsules In The Strength Of 0.375 G.Mesalamine Extended-Release Capsules Are Indicated For The Maintenance Of Remission Of Ulcerative Colitis In Adults.The Drug Will Be Manufactured At The Group&Rsquo;S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 320 Approvals And Has So Far Filed Over 400 Andas Since The Commencement Of The Filing Process In Fy 2003-04.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
